In the current study, we found that PI3K inhibition by BKM120 acts synergistically with PARP inhibition in abolishing the growth and survival of PIK3CA mutated ovarian cancer cells (SKOV3, HEYA8, and IGROV1) in in vitro assays as well as in an in vivo model of SKOV3 cells. The gene discussed is PIK3CA; the disease is ovarian cancer.